-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).
-
Summary
-
CNS Pharmaceuticals, Inc. quarterly/annual Nonoperating Income (Expense) history and growth rate from Q2 2019 to Q3 2024.
- CNS Pharmaceuticals, Inc. Nonoperating Income (Expense) for the quarter ending September 30, 2024 was $23K, a 108% increase year-over-year.
- CNS Pharmaceuticals, Inc. Nonoperating Income (Expense) for the twelve months ending September 30, 2024 was $24.6K, a 230% increase year-over-year.
- CNS Pharmaceuticals, Inc. annual Nonoperating Income (Expense) for 2023 was $13.9K.
- CNS Pharmaceuticals, Inc. annual Nonoperating Income (Expense) for 2022 was -$7.03K, a 24.3% increase from 2021.
- CNS Pharmaceuticals, Inc. annual Nonoperating Income (Expense) for 2021 was -$9.29K, a 184% decline from 2020.
Nonoperating Income (Expense), Trailing 12 Months (USD)
Nonoperating Income (Expense), Quarterly (USD)
Nonoperating Income (Expense), YoY Quarterly Growth (%)